Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial-Reference-Cited by-同舟云学术

Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial

Published:2016-12-02 Issue:2 Volume:10 Page:148-152
ISSN:1757-5664
Container-title:LUTS: Lower Urinary Tract Symptoms
language:en
Short-container-title:Lower Urinary Tract Symptoms

Author:

KINJO Manami¹,SEKIGUCHI Yuki²,YOSHIMURA Yasukuni³,NUTAHARA Kikuo¹

Affiliation:

1. Department of Urology, Kyorin University School of Medicine; Tokyo Japan

2. LUNA Pelvic Floor Total Support Clinic; Yokohama-shi Japan

3. Yotsuya Medical Cube; Tokyo Japan

Publisher

Wiley

Subject

Urology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/luts.12151/fullpdf

Reference21 articles.

1. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction;Haylen;Neurourol Urodyn,2010

2. An epidemiological survey of overactive bladder symptoms in Japan;Homma;BJU Int,2005

3. Prevalence and burden of overactive bladder in the United States;Stewart;World J Urol,2003

4. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur Urol,2006

5. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study;Coyne;BJU Int,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome;Perspectives in Clinical Research;2024-05-16

2. Predictors of non-persistence in women with overactive bladder syndrome;Scientific Reports;2024-03-29

3. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis;Advances in Therapy;2024-03-23

4. Cold stress‐induced bladder overactivity in type 2 diabetic mellitus rats is mitigated by the combination of a M ₃ ‐muscarinic antagonist and a β ₃ ‐adrenergic agonist;LUTS: Lower Urinary Tract Symptoms;2022-12-21

5. Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder;Medicine;2021-10-15